Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL). ALL is a rare, rapidly progressing cancer of the blood and bone marrow. The ...

NEW HAVEN, Conn. (WTNH) — A new Yale-led study published Thursday identified a new target for treating the most common form of cancer in children and young adults, B-cell acute lymphoblastic leukemia ...

Semi-structured interviews with children with ALL revealed a desire for clinicians to tell them about their disease directly in age-appropriate language.

New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...

Oncaspar (pegaspargase) is a long-acting prescription injection medicine used for people with a type of blood cancer known as acute lymphoblastic leukemia (ALL). It is also approved specifically for ...

Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are the most common pediatric cancers and among the leading causes of death in children. To improve kids’ chances of survival, early ...

In most cases, acute lymphoblastic leukemia (ALL) manifests as a de novo malignancy in previously healthy people. Risk factors for developing ALL include age older than 70 years and genetic disorders, ...

A combination of targeted treatment and immunotherapy has revolutionized Philadelphia chromosome–positive acute lymphoblastic leukemia management, achieving long-term survival rates of 75%-80% without ...

Asparlas (calaspargase pegol-mknl) is a long-acting prescription injection medicine used for people with a certain type of blood cancer known as acute lymphoblastic leukemia (ALL). It is approved in ...